Michael MERCHANT

Dr. Michael MERCHANT


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
LALaith Farah Al-Rabadi
Laith Farah Al-Rabadi
TCTiffany Caza
Tiffany Caza
CTClaire Trivin-Avillach
Claire Trivin-Avillach
ARAylin R. Rodan
Aylin R. Rodan
NANicole Andeen
Nicole Andeen
LBLaurence H. Beck
Laurence H. Beck
Significance Statement: Membranous nephropathy (MN) is a glomerular disease that often leads to nephrotic syndrome and is caused by autoantibodies that target podocyte proteins. Recent work has identified new targets in this disease, although many cases remain untyped, making clinical monitoring difficult. A combination of conventional and more novel techniques reveals a new target podocyte antigen in MN, serine protease HTRA1. Fourteen patients were identified in a demographic group with mean age of 67.3 years. The titer of circulating anti-HTRA1 antibodies appears to correlate with the disease course, suggesting serial monitoring could facilitate diagnostic and therapeutic decisions. Study of the function of HTRA1 may provide important clues to podocyte biology and the underlying pathogenesis of this type of MN. Background: Identification of target antigens PLA2R, THSD7A, NELL1, or Semaphorin-3B can explain the majority of cases of primary membranous nephropathy (MN). However, target antigens remain unidentified in 15%–20% of patients. Methods: A multipronged approach, using traditional and modern technologies, converged on a novel target antigen, and capitalized on the temporal variation in autoantibody titer for biomarker discovery. Immunoblotting of human glomerular proteins followed by differential immunoprecipitation and mass spectrometric analysis was complemented by laser-capture microdissection followed by mass spectrometry, elution of immune complexes from renal biopsy specimen tissue, and autoimmune profiling on a protein fragment microarray. Results: These approaches identified serine protease HTRA1 as a novel podocyte antigen in a subset of patients with primary MN. Sera from two patients reacted by immunoblotting with a 51-kD protein within glomerular extract and with recombinant human HTRA1, under reducing and nonreducing conditions. Longitudinal serum samples from these patients seemed to correlate with clinical disease activity. As in PLA2R- and THSD7A- associated MN, anti-HTRA1 antibodies were predominantly IgG4, suggesting a primary etiology. Analysis of sera collected during active disease versus remission on protein fragment microarrays detected significantly higher titers of anti-HTRA1 antibody in active disease. HTRA1 was specifically detected within immune deposits of HTRA1-associated MN in 14 patients identified among three cohorts. Screening of 118 “quadruple-negative” (PLA2R-, THSD7A-, NELL1-, EXT2-negative) patients in a large repository of MN biopsy specimens revealed a prevalence of 4.2%. Conclusions: Conventional and more modern techniques converged to identify serine protease HTRA1 as a target antigen in MN.

2 May 2018 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
MMMichael MERCHANT
Michael MERCHANT
MBMichael E. Brier
Michael E. Brier
MSMark S. Slaughter
Mark S. Slaughter
JKJon B. Klein
Jon B. Klein
KMKenneth R. McLeish
Kenneth R. McLeish
Acute kidney injury (AKI) is a common post-cardiac surgery complication and influences patient morbidity and prognosis. This study was designed to identify preoperative candidate urine biomarkers in patients undergoing cardiac surgery. A prospective cohort study of adults undergoing cardiac surgery at increased risk for AKI at a single hospital between July 2010 and September 2012 was performed. The primary outcome was the development of AKI, defined as an absolute serum creatinine (SCr) level increase ≥ 0.5 mg/dL or a ≥ 50% relative increase within 72 h of surgery. A secondary outcome was development of AKI defined by Kidney Disease Improving Global Outcomes (KDIGO). Urine collected by voiding within 4 h prior to surgery was used for proteomic analysis and confirmatory enzyme linked immunosorbent assays (ELISAs) studies. Biomarkers were tested for AKI-prediction using Cox and Snell R2, area under the receiver operating curve (AUROC), and percent of corrected classifications. To evaluate the added effect of each candidate biomarker on AKI discrimination, receiver operator characteristic (ROC) curves, integrated discrimination improvement (IDI), and net reclassification improvement (NRI) were calculated. Forty-seven of 755 patients met screening criteria including 15 with AKI. Proteomic analysis identified 29 proteins with a significant ≥2-fold change. Confirmatory ELISA measurements of five candidate markers showed urinary complement factor B (CFB) and histidine rich glycoprotein (HRG) concentrations were significantly increased in patients with AKI. By multivariate analysis, NRI, and IDI the addition of CFB and HRG to the standard clinical assessment significantly improved risk prediction for the primary outcome. Only HRG was a significant predictor in the 21 patients with AKI defined by KDIGO criteria. Pre-operative urine measurement of CFB or HRG significantly enhanced the current post-surgery AKI risk stratification for more restrictive definition of AKI. HRG, but not CFB or clinical risk stratification, predicted AKI defined by KDIGO. The ability of these biomarkers to predict risk for dialysis-requiring AKI or death could not be reliably assessed in our study due to a small number of patients with either outcome.

30 November 2010 in Advances in Chronic Kidney Disease
Verified
Journal Article
Closed access
PDF file
MMMichael MERCHANT
Michael MERCHANT
JKJon B. Klein
Jon B. Klein

1 November 2010 in Advances in Chronic Kidney Disease
Verified
Journal Article
Closed access
PDF file
MMMichael MERCHANT
Michael MERCHANT

16 April 2025 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
KSKatelyn R. Sheneman
Katelyn R. Sheneman
TCTimothy D. Cummins
Timothy D. Cummins
MMMichael MERCHANT
Michael MERCHANT
JHJoshua Hood
Joshua Hood
Silvia UriarteSilvia Uriarte
Silvia Uriarte
MLMatthew B. Lawrenz
Matthew B. Lawrenz
Yersinia pestis is the etiologic agent of the plague. A hallmark of plague is subversion of the host immune response by disrupting host signalling pathways required for inflammation. This non‐inflammatory environment permits bacterial colonization and has been shown to be essential for disease manifestation. Previous work has shown that Y. pestis inhibits phagocytosis and degranulation by neutrophils. Manipulation of these key vesicular trafficking pathways suggests that Y. pestis influences extracellular vesicle (EV) secretion, cargo selection, trafficking and/or maturation. Our goals were to define the EV population produced by neutrophils in response to Y. pestis and determine how these vesicles might influence inflammation. Towards these goals, EVs were isolated from human neutrophils infected with Y. pestis or a mutant lacking bacterial effector proteins known to manipulate host cell signalling. Mass spectrometry data revealed that cargoes packaged in EVs isolated from mutant infected cells were enriched with antimicrobial and cytotoxic proteins, contents which differed from uninfected and Y. pestis infected cells. Further, EVs produced in response to Y. pestis lacked inflammatory properties observed in those isolated from neutrophils responding to the mutant. Together, these data demonstrate that Y. pestis actively inhibits the production of antimicrobial EVs produced by neutrophils, likely contributing to immune evasion.

1 February 2017 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
BVBetty C. Villafuerte
Betty C. Villafuerte
MBMichelle T. Barati
Michelle T. Barati
MRMadhavi J. Rane
Madhavi J. Rane
SISusan Isaacs
Susan Isaacs
MLMing Li
Ming Li
MMMichael MERCHANT
Michael MERCHANT